Elizabeth G Rhee Selected Research

ceftolozane

1/2022	Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia.
1/2022	Exposure-Efficacy Analyses Support Optimal Dosing Regimens of Ceftolozane/Tazobactam in Participants with Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia in ASPECT-NP.
4/2021	Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal Clearance.
1/2020	Plasma pharmacokinetics of ceftolozane/tazobactam in pediatric patients with cystic fibrosis.
2/2019	The efficacy and safety of tazobactam/ceftolozane in Japanese patients with uncomplicated pyelonephritis and complicated urinary tract infection.
2/2019	The efficacy and safety of tazobactam/ceftolozane in combination with metronidazole in Japanese patients with complicated intra-abdominal infections.
1/2019	Ceftolozane-Tazobactam Population Pharmacokinetics and Dose Selection for Further Clinical Evaluation in Pediatric Patients with Complicated Urinary Tract or Complicated Intra-abdominal Infections.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Elizabeth G Rhee Research Topics

Disease

8	Infections 11/2021 - 06/2002
7	Bacterial Pneumonia 01/2022 - 01/2018
4	Healthcare-Associated Pneumonia 01/2022 - 12/2019
4	Urinary Tract Infections (Urinary Tract Infection) 01/2020 - 11/2018
3	Critical Illness (Critically Ill) 04/2021 - 12/2019
3	Intraabdominal Infections 01/2020 - 01/2019
3	Ventilator-Associated Pneumonia 01/2020 - 12/2019
2	AIDS-Related Complex (ARC) 10/2021 - 04/2021
1	Bacteremia 11/2021
1	Bacterial Infections (Bacterial Infection) 04/2021
1	Pneumonia (Pneumonitis) 01/2020
1	Cystic Fibrosis (Mucoviscidosis) 01/2020
1	Diarrhea 02/2019
1	Pyelonephritis 02/2019
1	Gram-Negative Bacterial Infections 01/2019
1	Body Weight (Weight, Body) 01/2019
1	HIV Infections (HIV Infection) 01/2014
1	Breast Neoplasms (Breast Cancer) 01/2014

Drug/Important Bio-Agent (IBA)

14	tazobactam drug combination ceftolozaneIBA 01/2022 - 01/2018
7	Tazobactam FDA LinkGeneric 01/2022 - 01/2019
7	ceftolozaneIBA 01/2022 - 01/2019
6	Meropenem (Merrem)FDA LinkGeneric 01/2022 - 12/2019
3	Cephalosporins (Cephalosporin Antibiotics)IBA 01/2020 - 01/2019
3	Pharmaceutical PreparationsIBA 12/2019 - 11/2018
2	CreatinineIBA 10/2021 - 04/2021
2	Anti-Bacterial Agents (Antibiotics)IBA 02/2019 - 11/2018
2	Imipenem Drug Combination Cilastatin (Primaxin)FDA Link 01/2018 - 01/2018
2	relebactamIBA 01/2018 - 01/2018
2	Proteins (Proteins, Gene)FDA Link 01/2014 - 06/2002
1	LactamsIBA 01/2021
1	Doripenem FDA Link 01/2020
1	Metronidazole (Metric)FDA LinkGeneric 02/2019
1	Alanine Transaminase (SGPT)IBA 02/2019
1	Integrase InhibitorsIBA 01/2014
1	Raltegravir Potassium FDA Link 01/2014
1	AntigensIBA 06/2002
1	OligodeoxyribonucleotidesIBA 06/2002
1	CPG-oligonucleotideIBA 06/2002
1	Vaccine AdjuvantsIBA 06/2002
1	Recombinant ProteinsIBA 06/2002

Therapy/Procedure

6	Mechanical Ventilators (Ventilator) 01/2022 - 01/2020
1	Artificial Respiration (Mechanical Ventilation) 12/2019
1	Intravenous Infusions 01/2019